Tag Archives: Enanta Pharmaceuticals

Oppenheimer Gives a Hold Rating to Enanta Pharmaceuticals (ENTA)

Oppenheimer analyst Jay Olson assigned a Hold rating to Enanta Pharmaceuticals (ENTA – Research Report) today and set a price target of $55.00. The company’s shares closed last Wednesday at $43.36, close to its 52-week low of $38.40. According to

Analysts Have Conflicting Sentiments on These Healthcare Companies: Enanta Pharmaceuticals (NASDAQ: ENTA), Perrigo Company (NYSE: PRGO) and ACADIA Pharmaceuticals (NASDAQ: ACAD)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Enanta Pharmaceuticals (ENTA – Research Report), Perrigo Company (PRGO – Research Report) and ACADIA Pharmaceuticals (ACAD – Research Report). Enanta Pharmaceuticals (ENTA) RBC Capital analyst

The Treas. & CFO of Enanta Pharmaceuticals is Exercising Options

Today it was reported that the Treas. & CFO of Enanta Pharmaceuticals (ENTA – Research Report), Paul Mellett, exercised options to buy 1,740 ENTA shares at $1.20 a share, for a total transaction value of $2,088. The options were close

Analysts Conflicted on These Healthcare Names: Enanta Pharmaceuticals (NASDAQ: ENTA) and Global Blood Therapeutics (NASDAQ: GBT)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Enanta Pharmaceuticals (ENTA – Research Report) and Global Blood Therapeutics (GBT – Research Report). Enanta Pharmaceuticals (ENTA) Oppenheimer analyst Jay Olson assigned a Hold rating

Enanta Pharmaceuticals (ENTA) Gets a Hold Rating from RBC Capital

RBC Capital analyst Brian Abrahams maintained a Hold rating on Enanta Pharmaceuticals (ENTA – Research Report) today and set a price target of $49.00. The company’s shares closed last Thursday at $53.04. According to TipRanks.com, Abrahams is a 5-star analyst

RBC Capital Maintains a Hold Rating on Enanta Pharmaceuticals (ENTA)

In a report issued on April 6, Brian Abrahams from RBC Capital maintained a Hold rating on Enanta Pharmaceuticals (ENTA – Research Report), with a price target of $49.00. The company’s shares closed last Tuesday at $50.92. According to TipRanks.com,